UBS AM’s ADC Therapeutics ADCT Stock Holding History

UBS AM’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-79,563	Closed	-$2.62M	–	2551
2020 Q3	$2.62M	Buy	79,563 +945	+1%	+$40.9K	﹤0.01%	1436
2020 Q2	$3.68M	Buy	+78,618	New	+$2.98M	﹤0.01%	1251

Other funds holding ADCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

VCG

Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return

Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

UBS AM's ADCT Position: Q4 2020 in Review

UBS AM sold out of ADC Therapeutics (ADCT) in Q4 2020, closing a stake of 79,563 shares — an estimated $2.62M sold.

UBS AM first reported a position in ADCT in Q2 2020 and held it in 2 quarters. The position peaked at $3.68M in Q2 2020. 51 funds tracked by Wall St. Rank hold ADCT as of Q4 2020.

UBS AM reported no remaining ADC Therapeutics position as of Q4 2020 after selling out during the quarter.
UBS AM sold 79,563 ADC Therapeutics shares in Q4 2020, an estimated $2.62M.
UBS AM first reported a position in ADC Therapeutics in Q2 2020 and held it in 2 quarters.
UBS AM's ADC Therapeutics position peaked at $3.68M in Q2 2020.
51 funds tracked by Wall St. Rank held ADC Therapeutics as of Q4 2020.

Based on UBS AM's 13F filing for Q4 2020, filed 17 Feb 2021.